American Society of Addiction Medicine
American Academy of Addiction Psychiatry
National Association for Alcohol and Drug Abuse Counselors
Substance Abuse and Mental Health Services Administration
Behavioral Health Services Treatment Locator
Bersani FS, Corazza O, Albano G, et al. (2014). 25C-NBOMe: Preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, vol. 2014, Article ID 734749. doi:10.1155/2014/734749. Retrieved October 5, 2015 from http://www.hindawi.com/journals/bmri/2014/734749/.
Brandt SD, King LA, Evans-Brown M. (2014). The new drug phenomenon. Drug Test Analysis 6: 587–97. doi: 10.1002/dta.1686. Retrieved September 29, 2015 from http://onlinelibrary.wiley.com/doi/10.1002/dta.1686/full.
Brents LK, Reichard EE, Zimmerman SM, et al. (2011). Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018. Retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS ONE 6(7): e21917. doi:10.1371/journal.pone.0021917. Retrieved October 5, 2015 from http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0021917.
Drug Enforcement Administration (DEA). (2013). JWH-018, 1-Pentyl-3-(1-naphthoyl) indole: Synthetic cannabinoid in herbal products. Retrieved August 18, 2015 from http://www.deadiversion.usdoj.gov/drug_chem_info/spice/spice_jwh018.pdf.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2015). Synthetic cathinones drug profile. Retrieved August 27, 2015 from http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones.
Falgiani M, Desai B, Ryan M. (2012). Bath salts intoxication: A case report. Case Reports in Emergency Medicine, vol. 2012, Article ID 976314. doi:10.1155/2012/976314. Retrieved October 5, 2015 from http://www.hindawi.com/journals/criem/2012/976314/.
Hohmann N, Mikus G, Czock D. (2014). Effects and risks associated with novel psychoactive substances: Mislabeling and sale as bath salts, spice, and research chemicals. Dtsch Arztebl Int 2014; 111(9):139–47; DOI: 10.3238/arztebl.2014.0139. Retrieved October 5, 2015 from http://www.aerzteblatt.de/int/archive/article?id=155702.
Johnston LD, O’Malley PM, Miech RA, et al. (2015). Monitoring the Future national survey results on drug use: 1975–2014: Overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan. Retrieved August 26, 2015 from http://monitoringthefuture.org//pubs/monographs/mtf-overview2014.pdf.
Karch SB. (2015). Cathinone Neurotoxicity (“The “3Ms”). Curr Neuropharmacol. 2015 Jan; 13(1):21–25. doi: 10.2174/1570159X13666141210225009. Retrieved October 5, 2015 from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462040/.
Krasowski MD, Ekins S. (2014). Using cheminformatics to predict cross reactivity of “designer drugs” to their currently available immunoassays. Journal of Cheminformatics 2014, 6:22. doi:10.1186/1758-2946-6-22. Retrieved October 5, 2015 from http://www.jcheminf.com/content/6/1/22.
National Center for Biotechnology Information (NCBI). (2015). Mephedrone. PubChem Open Chemistry Database. Retrieved September 18, 2015 from http://pubchem.ncbi.nlm.nih.gov/compound/45266826#section=Top.
National Institute on Drug Abuse (NIDA). (2015a). The science behind designer drugs. Retrieved September 29, 2015 from http://www.drugabuse.gov/news-events/latest-science/science-behind-designer-drugs.
National Institute on Drug Abuse (NIDA). (2015b). Commonly Abused Drugs Charts. Retrieved August 26, 2015 from http://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs-charts#mdma.
National Institute on Drug Abuse (NIDA). (2015c). “Flakka” (alpha-PVP). Retrieved September 21, 2015 from http://www.drugabuse.gov/emerging-trends/flakka-alpha-pvp.
National Institute on Drug Abuse (NIDA). (2014). Drugs of Abuse. Retrieved October 5, 2015 from http://www.drugabuse.gov/drugs-abuse.
Office of Diversion Control (ODC). Schedules of controlled substances: Temporary placement of three synthetic cannabinoids into Schedule I. Department of Justice, Drug Enforcement Administration. Retrieved August 27, 2015 from http://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr1219.htm.
Smith CD, Robert S. (2014). Designer drugs: Update on the management of novel psychoactive substance misuse in the acute care setting. Clin Med August 1, 2014 vol. 14 no. 4 409–415. doi: 10.7861/clinmedicine.14-4-409. Retrieved September 21, 2015 from http://www.clinmed.rcpjournal.org/content/14/4/409.long.
Substance Abuse and Mental Health Administration (SAMHSA). (2014). Hallucinogens. Retrieved October 5, 2015 from http://www.samhsa.gov/atod/hallucinogens.
United Nations Office on Drugs and Crime (UNODC). (2014a). UNODC Early Warning Advisory on New Psychoactive Substances. What are New Psychoactive Substances? Retrieved October 5, 2015 from https://www.unodc.org/LSS/Page/NPS.
United Nations Office on Drugs and Crime (UNODC). (2014b). Substance Groups. Retrieved August 26, 2015 from https://www.unodc.org/LSS/Substance.
Watterson LR, Olive MF. (2014). Synthetic cathinones and their rewarding and reinforcing effects in rodents. Advances in Neuroscience, vol. 2014, Article ID 209875. doi:10.1155/2014/209875. Retrieved September 18, 2015 from http://www.hindawi.com/journals/aneu/2014/209875/.
Weaver MF, John A Hopper JA, et al. (2015). Designer drugs 2015: Assessment and management. Addiction Science & Clinical Practice 2015, 10:8. doi:10.1186/s13722-015-0024-7. Retrieved September 18, 2015 from http://www.ascpjournal.org/content/10/1/8.